Results 151 to 160 of about 2,226,679 (338)

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Effects of Inhibitors of Protein Kinase C on the Release and Synthesis of Histamine in Rat Basophilic Leukemia Cells (2H3).

, 1992
Kazutaka Maeyama, Yoshitaka Taguchi, Eiko Sakurai, Masayuki Sasaki, Atsushi Yamatodani, Takehiko Watanabe   +5 more
openalex   +1 more source

Non‐canonical PKG1 regulation in cardiovascular health and disease

British Journal of Pharmacology, EarlyView.
It is well established that the cyclic GMP‐dependent protein kinase I (PKG1) is canonically activated by cyclic guanosine monophosphate (cGMP), enabling its regulation of vascular tone, cardiac function and smooth muscle homeostasis. However, diverse non‐canonical stimuli of PKG1 have also been identified.
Jie Su, Joseph Robert Burgoyne
wiley   +1 more source

Correspondence to ‘Hypersensitivity Reactions to Human Albumin—A Case Series and Diagnostic Algorithm’

Allergy, EarlyView.
Juliette Charpy, Mathilde Seydoux, Antoine Giraudon, Julien Bonnac, Maxime Dubois, Maryline Bordes‐Demolis, Christelle Pellerin, Julien Goret   +7 more
wiley   +1 more source

Critical role of the mast cell/tryptase/PAR2 axis in anastrozole‐induced pain

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Anastrozole, an aromatase inhibitor, is used to treat postmenopausal women with hormone receptor‐positive breast cancer, but also induces musculoskeletal pain and can lead to therapeutic regimen suspension. Aromatase inhibitors promote the release of pro‐inflammatory substances from sensitised nerve fibres, which might ...
Maria Fernanda Pessano Fialho, Raquel Tonello, Evelyne Silva Brum, Gabriela Becker, Nigel W. Bunnett, Sara Marchesan Oliveira   +5 more
wiley   +1 more source

Regional Differential Effects of the Novel Histamine H3 Receptor Antagonist 6-[(3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-3-pyridinecarboxamide hydrochloride (GSK189254) on Histamine Release in the Central Nervous System of Freely Moving Rats

Journal of Pharmacology and Experimental Therapeutics, 2010
P. Giannoni, A. Medhurst, M. Passani, M. Giovannini, C. Ballini, L. Corte, P. Blandina   +6 more
semanticscholar   +1 more source

Histamine-releasing factor: a promising therapeutic target for food allergy [PDF]

, 2017
Marsha Wills‐Karp
openalex   +1 more source

Evaluation of preclinical antipsychotic models used to support first‐in‐human clinical trials

British Journal of Pharmacology, EarlyView.
Abstract Schizophrenia is regarded as a complex and heterogeneous psychiatric disorder, characterised by diverse symptoms and comorbidities, which complicate both clinical management and drug development. Current pharmacological treatment, primarily based on dopamine D2 receptor antagonism or partial agonism, which has not markedly progressed since the
Thi Viet Ha Nguyen, Declan P. McKernan, John P. Kelly   +2 more
wiley   +1 more source

Gallic acid inhibits histamine release and pro-inflammatory cytokine production in mast cells.

Toxicological Sciences, 2006
Sang-Hyun Kim, C. Jun, K. Suk, B. Choi, Hyunjeung Lim, Seun-Ja Park, Seung Ho Lee, Hye-Young Shin, D. Kim, T. Shin   +9 more
semanticscholar   +1 more source

Inhibition of Compound 48/80-Mediated Histamine Release from Isolated Rat Mast Cells by Oosponol-Related Compounds (4-Acyl-Isocoumarins).

, 1978
Masayasu Kimura, Isami Waki, Masaya Kokubo   +2 more
openalex   +1 more source